Overview

Study of PEP02 as a Second Line Therapy for Metastatic Pancreatic Cancer

Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see the effect of PEP02 in the treatment of metastatic pancreatic cancer.
Phase:
Phase 2
Details
Lead Sponsor:
PharmaEngine
Treatments:
Irinotecan